Silexion Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLXN research report →
About the company
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor.
- CEO
- Ilan Hadar
- IPO
- 2024
- Employees
- 11
- HQ
- Jerusalem, IL
Price Chart
- Market Cap
- $1.11M
- P/E
- 0.05
- P/S
- 0.00
- P/B
- 2.94
- EV/EBITDA
- 0.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -516.87%
- ROIC
- 1448.83%
- Revenue
- $0 · 0.00%
- Net Income
- $-11,912,000 · 27.56%
- EPS
- $-89.60 · -239.39%
- Op Income
- $11.63M
- FCF YoY
- -28.63%
- 52W High
- $223.60
- 52W Low
- $2.31
- 50D MA
- $4.55
- 200D MA
- $18.84
- Beta
- -0.33
- Avg Volume
- 639.00K
Get TickerSpark's AI analysis on SLXN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 26 | Shirvan Mitchell | other | 6,000 |
| Jun 4, 26 | Horenshtein Hadar Mirit | other | 7,500 |
| Jun 4, 26 | Hadar Ilan | other | 10,000 |
| Mar 26, 26 | Shirvan Mitchell | sell | 22,818 |
| Feb 20, 26 | Noy Shlomo | other | 9,091 |
| Feb 20, 26 | Noy Shlomo | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 9,091 |
| Feb 20, 26 | Shirvan Mitchell | other | 49,726 |
| Feb 20, 26 | Horenshtein Hadar Mirit | other | 49,726 |
Our SLXN coverage
Recent articles, reports, and earnings notes.
No research on SLXN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SLXN report →Similar companies
Peers in the same neighborhood.